Peplomycin therapy for skin cancer in Japan.
Peplomycin was given in a dose of 5 mg daily, divided into two equal parts for intramuscular administration each morning and evening. This schedule not only augments the antitumour effect but also reduces adverse reactions to the drug. Peplomycin-mitomycin C (P-M) therapy improves the response rates in T3 and T4 cases of skin cancer, and is also effective in some N1, N3 and M1 cases. Continuous intra-arterial infusion of peplomycin, though requiring somewhat complicated procedures, is very effective against squamous cell carcinoma of the head, neck and extremities. Multidisciplinary therapy incorporating peplomycin has given a considerably higher five-year survival rate than that found in historical controls.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007261:Infusions, Intra-Arterial; D007564:Japan; D007700:Kinetics; D008168:Lung / Q000187:drug effects; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D017663:Peplomycin; D012878:Skin Neoplasms / Q000188:drug therapy*; D014212:Tretinoin / Q000008:administration & dosage
D008937:Mitomycins; D001761:Bleomycin; D016685:Mitomycin; D014212:Tretinoin; D017663:Peplomycin